BS_YZ2Z1Q6Y
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 34.49408672798948
- age_years
- 13.512
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.963 |
| 2 | BS_PQ7CQFYR | Ganglioglioma | — | 0.961 |
| 3 | BS_9F09XV62 | low-grade glioma | — | 0.957 |
| 4 | SJEPD031_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.946 |
| 5 | SRR1444876 | GTEX | — | 0.944 |
| 6 | BS_EXYHZ6D4 | pilocytic astrocytoma | — | 0.944 |
| 7 | SRR1316624 | GTEX | — | 0.943 |
| 8 | SRR1337431 | GTEX | — | 0.941 |
| 9 | BS_TCGEZJ5F | EPN | Supratentorial EPN | 0.941 |
| 10 | sclcMAD11162_S44.txt | — | cohortA1 | 0.940 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.447 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.352 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.331 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.248 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.218 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.193 | Inavolisib | — uncovered |
| COAGULATION | 0.173 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.125 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.094 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.088 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.027 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.027 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.026 | Idelalisib | — uncovered |
| COMPLEMENT | 0.021 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.015 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.012 | Remibrutinib | — uncovered |